JP2012514604A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514604A5
JP2012514604A5 JP2011544678A JP2011544678A JP2012514604A5 JP 2012514604 A5 JP2012514604 A5 JP 2012514604A5 JP 2011544678 A JP2011544678 A JP 2011544678A JP 2011544678 A JP2011544678 A JP 2011544678A JP 2012514604 A5 JP2012514604 A5 JP 2012514604A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
protease
coli
lipase
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011544678A
Other languages
English (en)
Other versions
JP2012514604A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/020259 external-priority patent/WO2010080835A1/en
Publication of JP2012514604A publication Critical patent/JP2012514604A/ja
Publication of JP2012514604A5 publication Critical patent/JP2012514604A5/ja
Withdrawn legal-status Critical Current

Links

Description

1つまたは複数の本発明の態様の詳細を添付の図面および以下の説明において示す。特許、特許出願、明細書、本、論文、科学出版物などの本明細書において開示される参考文献は全て、その全体が参照により組み入れられる。本発明の他の特徴、目的、および利点は、説明および図面ならびに特許請求の範囲から明らかであろう。
[本発明1001]
鳥または哺乳動物における大腸菌(E.coli)感染を治療または予防するための方法であって、1種類または複数の種類の消化酵素を含む治療的有効量の薬学的組成物を鳥または哺乳動物に投与する工程を含む、方法。
[本発明1002]
1種類または複数の種類の消化酵素が、プロテアーゼ、アミラーゼ、セルロース、スクラーゼ、マルターゼ、パパイン、およびリパーゼからなる群より選択される1種類または複数の種類の酵素を含む、本発明1001の方法。
[本発明1003]
1種類または複数の種類の消化酵素が1種類または複数の種類の膵臓酵素を含む、本発明1001の方法。
[本発明1004]
1種類または複数の種類の消化酵素がブタ酵素を含む、本発明1001の方法。
[本発明1005]
プロテアーゼがキモトリプシンおよびトリプシンを含む、本発明1002の方法。
[本発明1006]
1種類または複数の種類の消化酵素が、独立して、動物供給源、微生物供給源、植物供給源、真菌供給源に由来するか、または合成により調製される、本発明1001の方法。
[本発明1007]
哺乳動物が、ブタ、ウマ、ウシ、イヌ、ネコ、サル、ラット、マウス、ヒツジ、ヤギ、もしくはヒトであるか、または鳥が、ニワトリ、アヒル、シチメンチョウ、もしくはガチョウである、本発明1001の方法。
[本発明1008]
動物供給源がブタ膵臓である、本発明1006の方法。
[本発明1009]
薬学的組成物が、少なくとも1種類のアミラーゼと、キモトリプシンおよびトリプシンを含むプロテアーゼの混合物と、少なくとも1種類のリパーゼとを含む、本発明1001の方法。
[本発明1010]
薬学的組成物が、少なくとも1種類のプロテアーゼおよび少なくとも1種類のリパーゼを含み、全プロテアーゼと全リパーゼとの比(USP単位)が約1:1〜約20:1である、本発明1001の方法。
[本発明1011]
プロテアーゼとリパーゼとの比が約4:1〜約10:1である、本発明1011の方法。
[本発明1012]
薬学的組成物が、丸剤、錠剤、カプセル剤、カプレット、スプリンクル、クリーム、ローション剤、エアロゾル剤、エマルジョン、散剤、液剤、ゲル、およびそれらの任意の組み合わせからなる群より選択される投与製剤である、本発明1001の方法。
[本発明1013]
薬学的組成物が経口投与用に処方される、本発明1001の方法。
[本発明1014]
薬学的組成物が局部投与用に処方される、本発明1001の方法。
[本発明1015]
薬学的組成物がSTECに対して有効である、本発明1001の方法。
[本発明1016]
薬学的組成物がETECまたはEPECに対して有効である、本発明1001の方法。
[本発明1017]
大腸菌感染の1つまたは複数の症状を示す哺乳動物または鳥を治療する方法であって、1種類または複数の種類の消化酵素を含む治療的有効量の組成物を哺乳動物または鳥に投与する工程を含む、方法。
[本発明1018]
βラクタム抗生物質を哺乳動物または鳥に投与する工程をさらに含む、本発明1001または1017の方法。
[本発明1019]
個体における下痢を治療するための方法であって、1種類または複数の種類の消化酵素を含む薬学的組成物を個体に投与する工程を含む、方法。
[本発明1020]
個体が大腸菌に感染していると診断されている、本発明1019の方法。
[本発明1021]
大腸菌がSTECである、本発明1020の方法。
[本発明1022]
表面上にいる大腸菌の量を減らすために、または表面上にいる大腸菌を根絶するために表面を衛生化または消毒するための方法であって、1種類または複数の種類の消化酵素を含む組成物を該表面に適用する工程を含む、方法。
[本発明1023]
表面が非生物的表面または無生物表面である、本発明1022の方法。
[本発明1024]
表面が医療機器の表面である、本発明1023の方法。
[本発明1025]
表面が食品である、本発明1023の方法。
[本発明1026]
哺乳動物または鳥の皮膚領域、皮膚組織、または皮膚創傷に存在する大腸菌の量を減らすための方法であって、該皮膚領域、該皮膚組織、または該皮膚創傷に、1種類または複数の種類の消化酵素を含む組成物を適用する工程を含む、方法。
[本発明1027]
黄色ブドウ球菌(S.aureus)または大腸菌に対して>1〜約20のフェノール係数を有する、1種類または複数の種類の消化酵素を含む消毒剤。
[本発明1028]
大腸菌に対して殺菌性および/または静菌性である、1種類または複数の種類の消化酵素を含む抗生物質。
[本発明1029]
大腸菌に対して殺菌性および/または静菌性である、1種類または複数の種類の消化酵素を含む界面活性剤。
[本発明1030]
大腸菌に対して殺菌性および/または静菌性である、1種類または複数の種類の消化酵素を含む防腐剤。
[本発明1031]
大腸菌に対して殺菌性および/または静菌性である、1種類または複数の種類の消化酵素を含む消毒剤。

Claims (14)

  1. プロテアーゼ、アミラーゼ、およびリパーゼを含む消化酵素を含む薬学的組成物であって、大腸菌(E.coli)に対して殺菌性および/または静菌性であり、かつ抗生物質である、薬学的組成物。
  2. 鳥または哺乳動物における大腸菌感染を治療または予防する際の使用のための薬学的組成物であって、プロテアーゼ、アミラーゼ、およびリパーゼを含む消化酵素治療的有効量を含む、薬学的組成物
  3. 化酵素が、ルロース、スクラーゼ、マルターゼ、およびパパインからなる群より選択される1種類または複数の種類の酵素をさらに含む、請求項2記載の使用のための薬学的組成物
  4. プロテアーゼがキモトリプシンおよびトリプシンを含む、請求項2記載の使用のための薬学的組成物
  5. 化酵素が、独立して、動物供給源、微生物供給源、植物供給源、真菌供給源に由来するか、または合成により調製され、任意で動物供給源がブタ膵臓である、請求項2記載の使用のための薬学的組成物
  6. 全プロテアーゼと全リパーゼとの比(USP単位)が約1:1〜約20:1であり、任意でプロテアーゼとリパーゼとの比が約4:1〜約10:1である、請求項2記載の使用のための薬学的組成物
  7. 丸剤、錠剤、カプセル剤、カプレット、スプリンクル、クリーム、ローション剤、エアロゾル剤、エマルジョン、散剤、液剤、ゲル、およびそれらの任意の組み合わせからなる群より選択される投与製剤である、請求項2記載の使用のための薬学的組成物
  8. 経口投与用または局部投与用に処方される、請求項2記載の使用のための薬学的組成物
  9. STEC、ETEC、またはEPECに対して有効である、請求項2記載の使用のための薬学的組成物
  10. 大腸菌感染の1つまたは複数の症状を示す哺乳動物または鳥を治療する際の使用のための薬学的組成物であって、プロテアーゼ、アミラーゼ、およびリパーゼを含む1種類または複数の種類の消化酵素治療的有効量を含む、薬学的組成物
  11. βラクタム抗生物質さらに含む、請求項2または10記載の使用のための薬学的組成物
  12. 個体における下痢を治療する際の使用のための薬学的組成物であって、プロテアーゼ、アミラーゼ、およびリパーゼを含む1種類または複数の種類の消化酵素含む、薬学的組成物
  13. 個体が大腸菌に感染していると診断されており、任意で大腸菌がSTECである、請求項12記載の使用のための薬学的組成物
  14. 哺乳動物または鳥の皮膚領域、皮膚組織、または皮膚創傷に存在する大腸菌の量を減らすための方法であって、該皮膚領域、該皮膚組織、または該皮膚創傷に、プロテアーゼ、アミラーゼ、およびリパーゼを含む消化酵素を含む組成物を適用する工程を含む、方法。
JP2011544678A 2009-01-06 2010-01-06 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法 Withdrawn JP2012514604A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14271809P 2009-01-06 2009-01-06
US61/142,718 2009-01-06
US15327909P 2009-02-17 2009-02-17
US61/153,279 2009-02-17
US17085609P 2009-04-20 2009-04-20
US61/170,856 2009-04-20
PCT/US2010/020259 WO2010080835A1 (en) 2009-01-06 2010-01-06 Compositions and methods for the treatment or the prevention oral infections by e. coli

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015084102A Division JP6131513B2 (ja) 2009-01-06 2015-04-16 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2012514604A JP2012514604A (ja) 2012-06-28
JP2012514604A5 true JP2012514604A5 (ja) 2013-02-14

Family

ID=42316790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011544678A Withdrawn JP2012514604A (ja) 2009-01-06 2010-01-06 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
JP2015084102A Expired - Fee Related JP6131513B2 (ja) 2009-01-06 2015-04-16 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
JP2017069518A Pending JP2017122121A (ja) 2009-01-06 2017-03-31 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
JP2019003039A Active JP7149858B2 (ja) 2009-01-06 2019-01-11 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015084102A Expired - Fee Related JP6131513B2 (ja) 2009-01-06 2015-04-16 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
JP2017069518A Pending JP2017122121A (ja) 2009-01-06 2017-03-31 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
JP2019003039A Active JP7149858B2 (ja) 2009-01-06 2019-01-11 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法

Country Status (15)

Country Link
US (3) US9084784B2 (ja)
EP (2) EP2947100B1 (ja)
JP (4) JP2012514604A (ja)
KR (2) KR20170005191A (ja)
CN (2) CN102272162B (ja)
AU (1) AU2010203714C1 (ja)
BR (1) BRPI1007379B8 (ja)
CA (1) CA2747703C (ja)
ES (1) ES2727746T3 (ja)
GB (1) GB2480773B (ja)
HK (3) HK1162531A1 (ja)
HR (1) HRP20190922T1 (ja)
IL (3) IL213489A (ja)
NZ (1) NZ593823A (ja)
WO (1) WO2010080835A1 (ja)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2947100B1 (en) 2009-01-06 2019-05-08 Galenagen, LLC Oral compositions for the treatment or the prevention of infections by E. Coli
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
EP3056197A1 (en) * 2010-11-19 2016-08-17 Curemark, Llc Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
HUE050873T2 (hu) 2011-04-21 2021-01-28 Curemark Llc Vegyületek neuropszichiátriai rendellenességek kezelésére
US20130183364A1 (en) * 2012-01-12 2013-07-18 Corey BOTNER Antimicrobial product and method
US20130202581A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
US10828311B2 (en) * 2012-02-27 2020-11-10 Bayer New Zealand Limited Controlled release compositions and their methods of use
JP2015512402A (ja) 2012-03-30 2015-04-27 ゴジョ・インダストリーズ・インコーポレイテッド 抗菌性のアルコール泡沫組成物及びその調製法
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2016183090A1 (en) 2015-05-11 2016-11-17 Novabay Pharmaceuticals, Inc. Method of inactivating toxins using oxidative chlorine species
AU2016311235B2 (en) * 2015-08-24 2021-02-11 Smith & Nephew, Inc. Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms
JP6732454B2 (ja) * 2015-12-15 2020-07-29 サラヤ株式会社 洗浄殺菌剤組成物
CN108884453B (zh) 2016-01-31 2022-07-29 麦迪伍德有限公司 用于治疗伤口的清创组合物
IT201600077232A1 (it) * 2016-07-22 2018-01-22 Bio Optica Milano S P A Una preparazione liquida acquosa per la conservazione di un campione istologico
CN106376597A (zh) * 2016-08-30 2017-02-08 北京达成生物科技有限公司 一种多酶复合抑菌剂
GB201721430D0 (en) * 2017-12-20 2018-01-31 Q-Linea Ab Method and device for microscopy-based imaging of samples
US11123414B2 (en) * 2017-12-22 2021-09-21 Produits Naturasense Inc. Non-carcinogenic cream for delivery of active ingredient into the dermis
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN111499700B (zh) * 2020-05-06 2022-02-01 中国海洋大学 一种新型褐藻胶特异性结合蛋白及其制备与应用
KR102229800B1 (ko) * 2020-07-24 2021-03-19 (주)뉴젠사이언스 효소성분을 함유하는 소독용 조성물 및 그 제조 방법
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN117678599B (zh) * 2024-02-02 2024-04-16 山东安捷高科消毒科技有限公司 一种提高稳定性及杀菌效果的次氯酸消毒液及其制备方法

Family Cites Families (285)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE491927A (ja) 1948-10-30
US3002883A (en) 1959-07-29 1961-10-03 Dow Chemical Co Disinfectant compositions
GB928654A (en) 1960-10-25 1963-06-12 Philips Nv Improvements in or relating to the production of pancreatin
US3322626A (en) 1963-06-13 1967-05-30 Pannett Products Inc Medicinal composition for treating acne and method of using same
FR3071M (fr) 1963-10-18 1965-01-18 Centre Nat Rech Scient Nouvelles protéases pancréatiques, utilisables notamment en gastro-entérologie.
DE1517787A1 (de) 1965-12-06 1970-01-29 Takeda Chemical Industries Ltd Enzympraeparat und Verfahren zu seiner Herstellung
DE1617417A1 (de) 1966-12-08 1971-03-25 Ciba Geigy Pharmazeutisches Praeparat
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786615A (en) 1972-11-13 1974-01-22 Pfizer Process for preparing pre-moistened antimicrobial towels
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3860708A (en) 1973-11-15 1975-01-14 Philips Corp Method of delivering the intestines of human beings from bariumsulphate after barium meal examination
US3940478A (en) * 1974-04-29 1976-02-24 Sutures, Inc. Proteolytic enzymes as adjuncts to antibiotic prophylaxis of contaminated wounds
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
US4199322A (en) 1978-08-17 1980-04-22 The United States Of America As Represented By The Secretary Of Agriculture Antibacterial textile finishes utilizing zinc acetate and hydrogen peroxide
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
DE2923279B1 (de) 1979-06-08 1980-11-20 Kali Chemie Pharma Gmbh Verfahren zur Herstellung von Pankreatin-Pellets
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4432975A (en) 1981-04-13 1984-02-21 Icn Pharmaceuticals, Inc. Process for introducing vitamin B-12 into the bloodstream
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US5250418A (en) 1981-10-06 1993-10-05 Boehringer Mannheim Gmbh Process and reagent for determining the activity of chymotrypsin and trypsin in feces
US4395454A (en) 1981-10-09 1983-07-26 Burlington Industries, Inc. Absorbent microbiocidal fabric and product
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
DE3377506D1 (en) 1982-12-30 1988-09-01 Nordmark Arzneimittel Gmbh Process for obtaining pancreatin
EP0133438A1 (en) * 1983-01-21 1985-02-27 Advanced Drug Technology Corporation Enzyme ointment
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4456544A (en) * 1983-08-05 1984-06-26 Vsesojuzny Nauchno-Issledovatelsky Biotecknichesky Institut Enzyme-containing detergent composition for presterilization treatment of medical instruments and equipment
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
ATE116329T1 (de) 1985-12-03 1995-01-15 T Cell Sciences Inc Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
US5023108A (en) 1986-01-13 1991-06-11 Research Corporation Aqueous dispersions of waxes and lipids for pharmaceutical coating
JPS62230714A (ja) 1986-03-31 1987-10-09 Snow Brand Milk Prod Co Ltd 腸溶性カプセル
US4826679A (en) 1986-05-23 1989-05-02 Universite De Montreal Composition and methods for alleviating cystic fibrosis
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US4965012A (en) 1987-04-17 1990-10-23 Olson Keith E Water insoluble encapsulated enzymes protected against deactivation by halogen bleaches
DE3738599A1 (de) 1987-11-13 1989-05-24 Raps & Co Gewuerzwerk Eingekapselte trockenhefe in teilchenform, verfahren zu deren herstellung und verwendung derselben
WO1989008694A1 (en) 1988-03-14 1989-09-21 Novo-Nordisk A/S Granulate detergent enzyme product, method for production thereof, use thereof, and detergent containing such product
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
CN1039706A (zh) 1988-08-04 1990-02-21 黄族和 人造发菜的制作方法
GB8821049D0 (en) 1988-09-08 1988-10-05 Health Lab Service Board Method & composition for treatment & prevention of viral infections
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
GB8923788D0 (en) 1989-10-23 1989-12-13 Unilever Plc Enzymatic detergent compositions and their use
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
CA2030581C (en) 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
CA2037178A1 (en) 1990-02-28 1991-08-29 Albert Walter Brzeczko Deprenyl/l-dopa/carbidopa pharmaceutical composition
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5618710A (en) 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
NO920067L (no) 1991-01-14 1992-07-15 Ajinomoto Kk Foradditiv for droevtyggere
ATE136055T1 (de) 1991-04-30 1996-04-15 Procter & Gamble Gerüstsubstanzhaltige flüssigwaschmittel mit borsäure-polyolkomplex zur ptoteolytischen enzyminhibierung
EP0511456A1 (en) 1991-04-30 1992-11-04 The Procter & Gamble Company Liquid detergents with aromatic borate ester to inhibit proteolytic enzyme
US5607863A (en) 1991-05-29 1997-03-04 Smithkline Diagnostics, Inc. Barrier-controlled assay device
US5190775A (en) 1991-05-29 1993-03-02 Balchem Corporation Encapsulated bioactive substances
JPH04364119A (ja) 1991-06-11 1992-12-16 Tsumura & Co 浴剤組成物
IL99628A (en) 1991-10-02 2004-07-25 Yissum Res Dev Co Processes for the preparation of cyclic peptides, and pharmaceutical compositions containing them
EP0614353A1 (en) 1991-11-25 1994-09-14 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
US7242988B1 (en) 1991-12-23 2007-07-10 Linda Irene Hoffberg Adaptive pattern recognition based controller apparatus and method and human-factored interface therefore
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
GB9207280D0 (en) 1992-04-02 1992-05-13 Unilever Plc Skin care method and composition
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
DK0659083T3 (da) 1992-06-12 2000-06-13 Einstein Coll Med Forebyggelse og behandling af perifer neuropati
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
GB9218363D0 (en) 1992-08-28 1992-10-14 Black & Decker Inc Pivoting power tool with table
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
DE4305460C2 (de) 1993-02-23 1997-09-04 Albert Dr Scheller Pharmazeutische oder kosmetische, Enzyme enthaltende Zubereitung, Verfahren zu deren Herstellung und deren Verwendung
JPH06339343A (ja) 1993-04-08 1994-12-13 Ajinomoto Co Inc 反すう動物用飼料添加物
TW310277B (en) 1993-05-21 1997-07-11 Pou Lin Fu Gin Pharm Co The method of preparing enteric-coated pancreatin granules and its dosage forms
DE4332985A1 (de) 1993-09-28 1995-03-30 Konrad Peter Maria Dr Sommer Arzneimittel zur Behandlung der Dysfunktion des exokrinen Pankreas
GB9403250D0 (en) 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US20080311554A1 (en) 1994-05-06 2008-12-18 Slotman Gus J Methods for monitoring patients with severe sepsis and septic shock and for selecting treatments for these patients
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5476661A (en) 1994-10-21 1995-12-19 Elizabeth Arden Co., Division Of Conopco, Inc. Compositions for topical application to skin, hair and nails
US5527678A (en) 1994-10-21 1996-06-18 Vanderbilt University CagB and CagC genes of helicobacter pylori and related compositions
AUPN033894A0 (en) 1994-12-29 1995-01-27 Rowe, J.B. Prevention of adverse behaviour in humans and animals
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6558708B1 (en) 1995-05-17 2003-05-06 Cedars-Sinai Medical Center Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US5686255A (en) 1995-05-24 1997-11-11 Deth; Richard C. Compositions and methods for diagnosing schizophrenia
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
WO1997003693A1 (en) * 1995-07-21 1997-02-06 New York University Type ii phospholipase a2 and its use in killing gram-positive bacteria
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6852487B1 (en) 1996-02-09 2005-02-08 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
EP0884950B1 (en) 1996-03-06 2003-03-12 Novozymes A/S A method of killing or inhibiting microbial cells
US5958875A (en) 1996-03-29 1999-09-28 The Regents Of The University Of California Synthetic peptides derivatives with nerve growth factor-like neurotrophic activity
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
GB2318511A (en) 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
US5860932A (en) 1996-10-24 1999-01-19 Colin Corporation Blood pressure monitor
CA2190418A1 (en) 1996-11-15 1998-05-15 Zhi-Cheng Xiao Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
US6100080A (en) 1996-12-18 2000-08-08 Novo Nordisk A/S Method for enzymatic treatment of biofilm
WO1998032336A2 (en) 1997-01-22 1998-07-30 Kerry Ingredients (Uk) Limited Enzyme-based bread improvers
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
CA2198317C (en) 1997-02-24 2003-01-07 Mouhsine El Abboudi Method for preparing pancreatin which contains low amounts of residual organic solvent and product thereof
US6234964B1 (en) 1997-03-13 2001-05-22 First Opinion Corporation Disease management system and method
US5858758A (en) 1997-05-07 1999-01-12 Incyte Pharmaceuticals, Inc. Human serine protease precursor
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
JP2002501616A (ja) 1997-05-19 2002-01-15 リプリゲン コーポレーション 自閉的症候群を鑑別診断および治療する際の助けとするための方法
US6482839B1 (en) 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
AU7780598A (en) 1997-06-05 1998-12-21 Neuroimmuno Therapeutics Research Foundation Pharmaceutical composition containing transfer factor for treatment of inflam matory bowel disease and regressive behavioural disorder
GB2347742B (en) 1997-06-05 2001-11-07 Royal Free Hosp School Med Pharmaceutical composition for RBD
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
EP1051142A4 (en) 1997-10-16 2002-01-30 Deguang Zhu NEW STRONG COSMETIC OR PHARMACEUTICAL COMPOSITION
DE69839179T2 (de) 1997-10-28 2009-02-19 Bando Chemical Industries, Ltd., Kobe Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
EP0940088A3 (en) 1998-03-04 1999-12-15 Ajinomoto Co., Inc. Ruminant feed additive composition and process for producing the same
US20010024660A1 (en) 1999-09-29 2001-09-27 Ismat Ullah Enteric coated pharmaceutical composition and method of manufacturing
US6020314A (en) 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
ES2326502T3 (es) 1998-10-09 2009-10-13 General Mills, Inc. Encapsulacion de componentes liquidos sensibles en una matriz para obtener particulas discretas de larga conservacion.
US6149585A (en) 1998-10-28 2000-11-21 Sage Health Management Solutions, Inc. Diagnostic enhancement method and apparatus
US6168569B1 (en) 1998-12-22 2001-01-02 Mcewen James Allen Apparatus and method for relating pain and activity of a patient
US6753306B2 (en) 1998-12-23 2004-06-22 Joseph J. Simpson Germicidal and disinfectant composition
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
NZ514826A (en) 1999-03-17 2003-08-29 Solvay Pharm Gmbh Medicinal product for the treatment of diabetes
US7945451B2 (en) 1999-04-16 2011-05-17 Cardiocom, Llc Remote monitoring system for ambulatory patients
US6210950B1 (en) 1999-05-25 2001-04-03 University Of Medicine And Dentistry Of New Jersey Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors
US6153236A (en) 1999-06-03 2000-11-28 Balchem Corporation Low melt encapsulation with high laurate canola oil
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
CN1197617C (zh) 1999-06-18 2005-04-20 布亚纳森·乔·布拉吉 鱼丝氨酸蛋白酶及其在制药和化妆品上的应用
US7395216B2 (en) 1999-06-23 2008-07-01 Visicu, Inc. Using predictive models to continuously update a treatment plan for a patient in a health care location
JP4834266B2 (ja) 1999-08-13 2011-12-14 インタラクティブ メトロノーム, インコーポレイテッド 学習能力を向上させる方法及び装置
IL131508A (en) 1999-08-19 2006-12-10 David Cohen Micronexulatory formulations and controlled dispersion of isoflavins from rich masses of sesame and other plants
US6187309B1 (en) 1999-09-14 2001-02-13 Milkaus Laboratory, Inc. Method for treatment of symptoms of central nervous system disorders
US6447772B1 (en) 1999-10-01 2002-09-10 Klaire Laboratories, Inc. Compositions and methods relating to reduction of symptoms of autism
BR0014734A (pt) 1999-10-12 2002-06-18 Connex Ges Zur Optimierung Von Método melhorado para detectar microorganismos resistentes a ácido na evacuação
US6727073B1 (en) 1999-11-19 2004-04-27 Binax, Inc. Method for detecting enteric disease
US20020103675A1 (en) 1999-11-29 2002-08-01 John Vanelli Apparatus and method for providing consolidated medical information
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6251478B1 (en) 1999-12-22 2001-06-26 Balchem Corporation Sensitive substance encapsulation
US6564104B2 (en) 1999-12-24 2003-05-13 Medtronic, Inc. Dynamic bandwidth monitor and adjuster for remote communications with a medical device
US6980958B1 (en) 2000-01-11 2005-12-27 Zycare, Inc. Apparatus and methods for monitoring and modifying anticoagulation therapy of remotely located patients
JP5219322B2 (ja) 2000-02-14 2013-06-26 クリニカル ディシジョン サポート,エルエルシー 自動診断システムおよび方法
US6261613B1 (en) 2000-02-15 2001-07-17 General Mills, Inc. Refrigerated and shelf-stable bakery dough products
US6312741B1 (en) 2000-02-22 2001-11-06 Balchem Corporation Encapsulated food acids for preservation of baked goods
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US7379885B1 (en) 2000-03-10 2008-05-27 David S. Zakim System and method for obtaining, processing and evaluating patient information for diagnosing disease and selecting treatment
CA2342121C (fr) 2000-03-29 2010-05-25 Roquette Freres Mannitol pulverulent et son procede de preparation
US6399101B1 (en) 2000-03-30 2002-06-04 Mova Pharmaceutical Corp. Stable thyroid hormone preparations and method of making same
AUPQ679100A0 (en) 2000-04-07 2000-05-11 Novapharm Research (Australia) Pty Ltd Process and composition for cleaning medical instruments
US6399114B2 (en) 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
US6783757B2 (en) 2000-06-01 2004-08-31 Kirkman Group, Inc. Composition and method for increasing exorphin catabolism to treat autism
US20040062757A1 (en) 2001-06-05 2004-04-01 Finegold Sydney M. Method of testing gastrointestinal diseases associated with species of genus clostridium
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002014537A2 (en) 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20020094367A1 (en) 2000-09-08 2002-07-18 Novozymes A/S Dough composition
WO2002019828A1 (en) 2000-09-08 2002-03-14 Novozymes A/S A dough composition comprising a lipid-encapsulated enzyme
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US20020119914A1 (en) 2000-12-26 2002-08-29 Deguang Zhu New uses of insulin and pancreatin
US6548556B2 (en) 2000-12-27 2003-04-15 Healthpoint, Ltd. Stable enzymatic wound debrider
GB2370839A (en) 2001-01-06 2002-07-10 Benedikt Timmerman Immunogenic complex useful for disease control
CN1150032C (zh) 2001-01-15 2004-05-19 孙芳梅 治疗小儿腹泻浓缩颗粒及其制备工艺
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
US7107996B2 (en) 2001-04-10 2006-09-19 Ganz Robert A Apparatus and method for treating atherosclerotic vascular disease through light sterilization
US7034134B2 (en) * 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7232670B2 (en) 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
US7101573B2 (en) 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
US7630911B2 (en) 2001-10-24 2009-12-08 Qtc Management, Inc. Method of automated processing of medical data for insurance and disability determinations
AU2002364750A1 (en) * 2001-12-14 2003-06-30 Solvay Pharmaceuticals Gmbh Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
US6797291B2 (en) 2002-01-09 2004-09-28 Balchem Corporation Stable hygroscopic compositions and methods for stabilizing hygroscopic ingredients
US6616954B1 (en) 2002-03-14 2003-09-09 Balchem Corporation Solvent released encapsulated yeast
US7226771B2 (en) 2002-04-19 2007-06-05 Diversa Corporation Phospholipases, nucleic acids encoding them and methods for making and using them
EP2266525B1 (en) 2002-05-03 2012-07-11 Martek Biosciences Corporation High quality lipids and methods for producing by enzymatic liberation from biomass
MXPA05001520A (es) 2002-07-08 2005-05-05 Joe S Wilkins Jr Formulaciones antibacteriales.
US20040005304A1 (en) 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
EP1578935A2 (en) * 2002-10-10 2005-09-28 Diversa Corporation Proteases, nucleic acids encoding them and methods for making and using them
EP1413202A1 (en) 2002-10-22 2004-04-28 CSM Nederland B.V. Lipid-encapsulated functional bakery ingredients
US20050079594A1 (en) 2002-10-31 2005-04-14 Karine Marion Method of removing a biofilm
US6835397B2 (en) 2002-12-23 2004-12-28 Balchem Corporation Controlled release encapsulated bioactive substances
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
JP2007523664A (ja) 2003-04-23 2007-08-23 フェリング ベスローテン フェンノートシャップ 医薬組成物用サシェ
US7780595B2 (en) 2003-05-15 2010-08-24 Clinical Decision Support, Llc Panel diagnostic method and system
CA2525366A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
CN100487098C (zh) 2003-06-05 2009-05-13 柯积发 纳米除菌无磷洗衣粉
ATE454154T1 (de) * 2003-06-19 2010-01-15 Nicholas S Bodor Steigerung der aktivität und/oder der wirkungsdauer weicher steroide mit anti- entzündungswirkung für topische oder lokale verabreichung
US7289761B2 (en) 2003-06-23 2007-10-30 Cardiac Pacemakers, Inc. Systems, devices, and methods for selectively preventing data transfer from a medical device
US7354569B2 (en) 2003-07-11 2008-04-08 Colgate-Palmolive Company Chewable antiplaque confectionery dental composition
CN1809753B (zh) 2003-07-29 2010-10-20 索尔瓦药物有限公司 通过二维凝胶电泳分析包含生理可接受消化酶混合物的方法
US7785584B2 (en) 2003-08-13 2010-08-31 Healthpoint, Ltd. Ointment wound spray
DK1663298T3 (da) 2003-09-23 2019-10-14 Dsm Ip Assets Bv Anvendelse af prolinspecifikke endoproteaser til hydrolyse af peptider og proteiner
US7381698B2 (en) 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US20050187130A1 (en) * 2004-02-23 2005-08-25 Brooker Alan T. Granular laundry detergent composition comprising an anionic detersive surfactant, and low levels of, or no, zeolite builders and phosphate builders
AU2005227090B2 (en) 2004-03-22 2010-12-09 Abbott Laboratories Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
US20050232894A1 (en) 2004-04-20 2005-10-20 Weiner Gregory M Antimicrobial skin treatment composition and methods for producing and using an antimicrobial skin treatment composition
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
DE602005022187D1 (de) 2004-05-24 2010-08-19 Novozymes As Enzyme für pharmazeutische anwendung
ITTO20040390A1 (it) 2004-06-10 2004-09-10 Roeder 1956 Farmaceutici S P A Composizione, in particolare per uso farmaceutico, ad azione antiossidante, antinfiammatoria ed immunostimolante.
WO2006009764A1 (en) 2004-06-17 2006-01-26 Amano Enzyme Usa., Ltd. Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
WO2006019764A2 (en) 2004-07-15 2006-02-23 Northstar Neuroscience, Inc. Systems and methods for enhancing or affecting neural stimulation efficiency and/or efficacy
CN103181400B (zh) 2004-09-10 2016-08-10 诺维信北美公司 防止、去除、减少或破坏生物膜的方法
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
PT2198880T (pt) * 2004-10-14 2017-01-04 Lilly Co Eli Composições contendo lipase, protease e amilase para o tratamento de insuficiência pancreática
CN101039667A (zh) 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
US20060115467A1 (en) 2004-12-01 2006-06-01 Pangborn Jon B Compositions and methods for the treatment of autism
EP1861009B1 (en) 2005-03-17 2019-05-22 Robert E. Coifman Apparatus and method for intelligent electronic peak flow meters
US20060294108A1 (en) 2005-04-14 2006-12-28 Adelson Alex M System for and method of managing schedule compliance and bidirectionally communicating in real time between a user and a manager
US20070092501A1 (en) 2005-04-26 2007-04-26 Prothera, Inc. Compositions and methods relating to reduction of symptoms of autism
US20060258599A1 (en) 2005-04-27 2006-11-16 Melanie Childers Methods and composition for the treatment of cystic fibrosis and related illnesses
US20060258708A1 (en) 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
JP2008542378A (ja) 2005-05-31 2008-11-27 オレキシジェン・セラピューティクス・インコーポレーテッド 精神病性障害を管理する方法および組成物
US20070116699A1 (en) 2005-06-24 2007-05-24 N-Zymeceuticals, Inc. Nattokinase for reducing whole blood viscosity
UA93384C2 (ru) 2005-07-29 2011-02-10 Солвей Фармасьютикалс Гмбх Способ получения стерилизированного порошкообразного панкреатина
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
EP1931317B1 (en) 2005-08-15 2008-12-24 Solvay Pharmaceuticals GmbH Pancreatin micropellets suitable for enteric coating
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US20100196344A1 (en) 2005-10-14 2010-08-05 Cystic Fibrosis Foundation Therapeutics, Inc. Compositions and methods for treating pancreatic insufficiency
US20070203426A1 (en) 2005-10-20 2007-08-30 Kover Arthur J Method and apparatus for obtaining real time emotional response data over a communications network
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US8728521B2 (en) 2005-12-27 2014-05-20 Hemant N. Joshi Physically/molecularly distributed and/or chemically bound medicaments in empty, hard capsule shells
ES2763724T3 (es) 2005-12-27 2020-05-29 Univ Ramot Preparaciones enzimáticas estables y métodos de uso de las mismas
AU2007211641B2 (en) 2006-02-02 2012-09-06 Dsm Ip Assets B.V. Food product comprising a proline specific protease
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
EP2032612A1 (en) 2006-06-23 2009-03-11 Basell Poliolefine Italia S.r.l. Magnesium chloroalkolate-based catalyst precursors
US20080019956A1 (en) 2006-07-24 2008-01-24 Manoj Kumar Enzymatic prevention and control of biofilm
US8287858B2 (en) 2006-08-10 2012-10-16 Jon Barron Proteolytic enzyme formulations
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
DE102006053071A1 (de) 2006-11-10 2008-05-15 Ab Enzymes Gmbh Protein-enthaltender Stoff mit erhöhter Temperaturstabilität
US8066986B2 (en) * 2007-02-01 2011-11-29 Master Supplements, Inc. Formulations including digestive enzymes and polysorbate surfactants that enhance the colonization of administered probiotics microoganisms
US20080199448A1 (en) * 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US20090117180A1 (en) 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
WO2008102264A2 (en) 2007-02-20 2008-08-28 Eurand Pharmaceuticals Limited Stable digestive enzyme compositions
AU2008239737A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
JP2008283895A (ja) * 2007-05-16 2008-11-27 Osaka City Univ 下痢原性大腸菌検出方法
US20090004285A1 (en) 2007-06-29 2009-01-01 Liangping Yu Stable non-disintegrating dosage forms and method of making same
CA2697990A1 (en) 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US20090063402A1 (en) 2007-08-31 2009-03-05 Abbott Diabetes Care, Inc. Method and System for Providing Medication Level Determination
US20090110674A1 (en) 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
RU2356244C1 (ru) 2007-11-12 2009-05-27 Федеральное государственное учреждение "Томский научно-исследовательский институт курортологии и физиотерапии Федерального агентства по здравоохранению и социальному развитию" (ФГУ "ТНИИКиФ Росздрава") Способ комплексного лечения детей с целиакией на санаторно-курортном этапе
US20090171696A1 (en) 2008-01-02 2009-07-02 David Joseph Allard System and method for patient portal with clinical decision intelligence
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8976007B2 (en) 2008-08-09 2015-03-10 Brian M. Dugan Systems and methods for providing biofeedback information to a cellular telephone and for using such information
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
WO2009155689A1 (en) 2008-06-24 2009-12-30 Micropharma Limited Nitric oxide device and method for wound healing, treatment of dermatological disorders and microbial infections
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US20090324730A1 (en) 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
WO2010002972A1 (en) 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
WO2010025126A1 (en) 2008-08-26 2010-03-04 Cystic Fibrosis Foundation Therapeutics, Inc. Rapidly disintegrating tablets comprising lipase, amylase, and protease
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2295086B1 (de) 2008-11-03 2012-01-18 Nordmark Arzneimittel GmbH & Co.KG Verfahren zur Verringerung der viralen und mikrobiellen Belastung von Pankreatin
EP2947100B1 (en) 2009-01-06 2019-05-08 Galenagen, LLC Oral compositions for the treatment or the prevention of infections by E. Coli
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
WO2010096814A1 (en) 2009-02-23 2010-08-26 Eurand, Inc. Controlled-release compositions comprising a proton pump inhibitor
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
EP2295039B2 (de) 2009-08-28 2022-10-26 Nordmark Pharma GmbH Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets
WO2011029054A1 (en) 2009-09-04 2011-03-10 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
US20110081320A1 (en) 2009-10-06 2011-04-07 Nubiome, Inc. Treatment/Cure of Autoimmune Disease
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
US20110112005A1 (en) 2009-11-12 2011-05-12 Alan Thomas Brooker Laundry Detergent Composition
WO2011086126A1 (en) 2010-01-15 2011-07-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds for the treatment of autism
US20110200574A1 (en) 2010-02-02 2011-08-18 Jolly James F Use of proteases for gluten intolerance
JP2013522285A (ja) 2010-03-19 2013-06-13 アプタリス・ファーマ・カナダ・インコーポレイテッド 膵酵素調合物におけるウィルスの不活性化のためのβ−プロピオラクトン
SE535296C2 (sv) 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
CL2011002432A1 (es) 2010-10-01 2012-04-20 Aptalis Pharma Ltd Composicion que comprende al menos una enzima digestiva y al menos un portador, en donde el portador comprende celulosa microcristalina que tiene un tamaño de particulas mayor que 100 um; una forma de dosificacion; el envase que la contiene; un proceso para preparar la composicion; y sus usos.
EP3056197A1 (en) 2010-11-19 2016-08-17 Curemark, Llc Preparation and use of combination enzyme and gastrointestinal modulator delivery systems
AU2012205681B2 (en) 2011-01-10 2016-07-28 Cleveland Biolabs, Inc. Use of toll-like receptor agonist for treating cancer
HUE050873T2 (hu) 2011-04-21 2021-01-28 Curemark Llc Vegyületek neuropszichiátriai rendellenességek kezelésére
BR112014016557A8 (pt) 2012-01-03 2017-07-04 Curemark Llc métodos de tratamento de sintomas comportamentais de distúrbios neurológicos e mentais
US20130202581A1 (en) * 2012-02-02 2013-08-08 Curelon Llc Enzyme compositions and use thereof for wound healing
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction

Similar Documents

Publication Publication Date Title
JP2012514604A5 (ja)
JP7149858B2 (ja) 大腸菌(E.coli)による経口感染の治療または予防のための組成物および方法
Jadhav et al. Serratiopeptidase: Insights into the therapeutic applications
KR101694930B1 (ko) 스타필로코쿠스 아우레우스 감염의 치료 또는 예방 및 표면 상의 스타필로코쿠스 아우레우스의 박멸 또는 감소를 위한 조성물 및 방법
JP2012514602A5 (ja)
Gerits et al. New approaches to combat Porphyromonas gingivalis biofilms
Nidadavolu et al. Garlic ointment inhibits biofilm formation by bacterial pathogens from burn wounds
JP2018138608A (ja) 特定の症状に関連するバイオフィルムの抑制及び治療のための、セラチア・ペプチダーゼを含む組成物及び方法
US20060228384A1 (en) Control of biofilm with a biofilm inhibitor
AU2017239486B2 (en) Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
WO2005123137A3 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride